Gastric cancer (GC) is a complex and heterogeneous disease that represents the third leading cause of cancer death in both sexes worldwide. GC management is hindered by the limited efficacy of current therapies and it is thus mandatory to develop novel strategies and identify predictive markers for the stratification of patients expected to benefit from targeted therapies.

GRAMMY proposes a novel multilevel approach integrating high impact basic, translational and psychological/social research towards developing an optimized patient stratification tool for the early prediction of therapy-resistant GC patient groups. Targeted actions aim to: determine comprehensive profiles of cellular, molecular and immune phenotypes of GC tumours; validate non-invasive tools for treatment monitoring; develop patient-specific drug-response pre-clinical models; determine each patient’s psycho/sociological and physician-patient interaction profiles and develop a personalized prediction tool by integrating each patient’s biological and psycho/sociological traits. Integration of such multi-nodal data represents a challenge towards identifying the putative links between disease-specific cellular and molecular characteristics, patient perception and therapy response.